April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
The Study of IL-17A Expression as a Biomarker for Patients With Active Noninfectious Uveitis Treated With AIN457
Author Affiliations & Notes
  • R. R. Buggage
    Novartis Pharmaceuticals Corp, New York, New York
  • H. B. Richards
    Novartis Institutes for Biomedical Research, Basel, Switzerland
  • M.-A. Valentin
    Novartis Institutes for Biomedical Research, Basel, Switzerland
  • I. Koroleva
    Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
  • T. B. Dryja
    Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
  • Footnotes
    Commercial Relationships  R.R. Buggage, Novartis, E; H.B. Richards, Novartis, E; M.-A. Valentin, Novartis, E; I. Koroleva, Novartis, E; T.B. Dryja, Novartis, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3779. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. R. Buggage, H. B. Richards, M.-A. Valentin, I. Koroleva, T. B. Dryja; The Study of IL-17A Expression as a Biomarker for Patients With Active Noninfectious Uveitis Treated With AIN457. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3779. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Higher IL-17 expression has been detected in patients with active uveitis and Behçet’s disease compared to patients with inactive disease and healthy controls. AIN457 offers a novel therapeutic strategy for noninfectious uveitis including Behçet’s uveitis. The effect of AIN457 on IL-17A expression and the correlation between baseline IL-17A and treatment response were evaluated in an open-label study.

Methods: : 16 patients with active noninfectious uveitis of various etiologies were treated with 2 intravenous doses of AIN457 at day 0 and 21 and followed through week 8. Serum IL-17A was measured on day 0 using a highly sensitive immunoassay coupled to single photon detection and mRNA levels were measured on day 0, weeks 1,2,3,4 and 8 by RT-PCR.

Results: : Treatment with AIN457 reduced intraocular inflammation, improved visual acuity or allowed for reduction of concomitant corticosteroids in 11/16 patients. While the mean baseline IL-17A level in patients with active uveitis was higher than in healthy subjects (0.47 vs 0.26 pg/ml; p=0.05), the difference was mainly due to a single outlier. After excluding this patient, there was no significant difference in baseline IL-17A levels comparing study patients and controls. Poor correlation existed between baseline serum IL-17A protein levels and IL-17A mRNA expression in whole blood. No obvious relationship existed between IL-17A mRNA levels in whole blood and response to treatment.

Conclusions: : Although baseline serum levels and expression of IL-17A were not elevated in this active uveitis study population, the clinical findings support the role of IL-17A in the pathogenesis of human uveitis and suggest that IL-17A inhibition with AIN457 may be efficacious for the treatment of noninfectious uveitis. Moreover these results indicate that ocular elevation of IL-17A may be locally confined and not measurable in the circulation. Additional studies are needed to understand the value of measuring circulating IL-17A in patients with noninfectious uveitis as a potential biomarker predictive of response to therapy with AIN457.

Clinical Trial: : www.clinicaltrials.gov NCT00685399

Keywords: uveitis-clinical/animal model • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.